Topics

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

2020-03-31 04:03:56 | BioPortfolio

Summary

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

Description

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.

Study Design

Conditions

Multiple Myeloma

Intervention

C-CAR088

Location

InstituteHBDH
TianJin
China
300000

Status

Recruiting

Source

Institute of Hematology & Blood Diseases Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-03-31T04:03:56-0400

Clinical Trials [1664 Associated Clinical Trials listed on BioPortfolio]

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patients.

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment....

PubMed Articles [5697 Associated PubMed Articles listed on BioPortfolio]

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitar...

No decrease in fracture risk despite 15 years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study.

While treatment strategies for multiple myeloma have evolved radically over the last decades, little is known about the risk of fractures for symptomatic multiple myeloma patients over time.

Multiple Myeloma and Chemical Maxillary Osteonecrosis. Can both occur simultaneously?

The aim of the present study was to investigate the number of patients with Multiple Myeloma (MM) treated with intravenous Zoledronic Acid who presented an involvement of the jaws by Myeloma that mimi...

Multiple Myeloma: 2020 update on Diagnosis, Risk-stratification and Management.

Multiple myeloma accounts for approximately 10% of hematologic malignancies.

Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

All patients who develop multiple myeloma have a preceding asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering mult...

Medical and Biotech [MESH] Definitions

An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

More From BioPortfolio on "A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma"

Quick Search

Searches Linking to this Trial